Our Technology

Trillium Therapeutics is an immuno-oncology company dedicated to the discovery and development of novel and innovative cancer therapies. We have two premier pre-clinical programs, SIRPαFc and a CD200 monoclonal antibody, which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. 

Thumb Download


Email Address: *
First Name:
Mailing Lists

Enter the code shown above.

Powered By Q4 Inc.